CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.93 Average Price Target from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned an average recommendation of “Hold” from the seventeen analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $73.57.

Several equities analysts recently commented on the stock. Robert W. Baird upped their price target on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Oppenheimer reduced their price objective on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Citigroup reduced their price objective on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday. Mizuho increased their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Finally, Barclays reduced their price objective on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 9th.

CRISPR Therapeutics Trading Down 1.9 %

NASDAQ CRSP opened at $55.73 on Friday. CRISPR Therapeutics has a 1 year low of $37.55 and a 1 year high of $91.10. The firm has a market capitalization of $4.73 billion, a P/E ratio of -20.49 and a beta of 1.80. The firm’s fifty day moving average price is $60.59 and its two-hundred day moving average price is $65.51.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $25.53 million. During the same quarter in the prior year, the company posted ($0.67) EPS. CRISPR Therapeutics’s revenue was down 99.5% on a year-over-year basis. On average, research analysts anticipate that CRISPR Therapeutics will post -5.64 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the sale, the chief executive officer now owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the sale, the chief executive officer now owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,801 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $78.26, for a total transaction of $219,206.26. Following the sale, the general counsel now directly owns 60,070 shares of the company’s stock, valued at approximately $4,701,078.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,709 shares of company stock valued at $3,865,228. 4.10% of the stock is currently owned by company insiders.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Riggs Asset Managment Co. Inc. grew its position in shares of CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after buying an additional 200 shares during the period. Orion Capital Management LLC grew its position in shares of CRISPR Therapeutics by 44.0% during the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after buying an additional 220 shares during the period. Signaturefd LLC grew its position in shares of CRISPR Therapeutics by 12.5% during the 3rd quarter. Signaturefd LLC now owns 2,124 shares of the company’s stock worth $96,000 after buying an additional 236 shares during the period. Itau Unibanco Holding S.A. grew its position in shares of CRISPR Therapeutics by 10.8% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock worth $114,000 after buying an additional 245 shares during the period. Finally, Spire Wealth Management grew its position in shares of CRISPR Therapeutics by 32.7% during the 3rd quarter. Spire Wealth Management now owns 1,052 shares of the company’s stock worth $48,000 after buying an additional 259 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.